ADGRB3 is an angiogenesis inhibitor, which has been found to be the most significantly mutated gene in 13% of lung squamous tumours, with mutations resulting in decreased activity of the receptor, increasing blood flow to the tumour [74]. The gene discussed is ADGRB3; the disease is neoplasm.